About MAIA Biotechnology, Inc. MAIA is a targeted ... progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product ...

PanGIA Biotech, a company advancing urine-based ... biopsy (Abstract #3080), has been accepted for presentation in the poster session titled Developmental Therapeutics—Molecularly Targeted ...

Issued on behalf of Oncolytics Biotech Inc. Specifically ... in activating anti-tumor immunity in PDAC,” (Abstract #2562) ...

MAIA Biotechnology, Inc., (NYSE American ... a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking ...

The BRITE High School Student Symposium welcomes all high school students who want to explore biotechnology and ... who’ve conducted their own research. While students have the option to submit an ...

REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (PPBT ... today announced upcoming poster presentations including one for CM24 in the treatment of pancreatic cancer ...

SPARTANBURG COUNTY, S.C. (WSPA) – A biotech research and development center announced that they have plans to set up operations in Spartanburg County. Related video: $19M childcare campus coming ...

PanGIA Biotech, a company advancing urine-based, AI-driven diagnostics for early cancer detection, today announced that an abstract co-authored by researchers from PanGIA Biotech, Entopsis Inc ...

Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC) MAIA Biotechnology ... studies and our research and development programs ...

CHICAGO, May 15, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American ... about the efficacy data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 ...